Search for a trial

Phase I First Time in Human Open Label Study of GSK3745417 administered with and without Anticancer Agents in Participants with Advanced Solid Tumors (study 208850)

Primary (PART 1A ONLY):Dose escalation: To determine the safety, tolerability, and the recommended phase 2 dose (RP2D) of GSK3745417 alone administered intravenously to participants with selected advanced/recurrent solid tumors.Secondary: (PART 1A…

A Phase 2, Single-Arm, Open-Label Study with Dostarlimab Monotherapy in Participants with Untreated Stage II/III dMMR/MSI-H Locally Advanced Rectal Cancer

This study has been transitioned to CTIS with ID 2023-509583-22-00 check the CTIS register for the current data. Primary objective:To estimate the efficacy of dostarlimab in participants with Stage II/III (locally advanced) dMMR/MSI-H rectal cancer…